biotech investment

Biotech investment is scarce, but still available, experts tell CEOs

Even in this challenging market, biotechnology firms are attracting investment and building capital, ...
Read More
M&A in biotech

What biotech companies should know about M&A in down markets

Mergers and acquisitions (M&A) are important elements of the biotech industry, especially for ...
Read More
IMG_3735

The future of next-generation obesity drugs

The metabolic field is the hottest biotech therapeutic area of the year (and ...
Read More
us-capitol-gdb89d0072_640

CEOs ask Congress to pass ORPHAN Cures Act

Biotechnology Innovation Organization (BIO) member companies and CEOs sent a letter to congressional ...
Read More
AI drug development

Drug developers and investors need to join AI revolution, panel says

Artificial intelligence and machine learning have boosted drug development and enhanced the value ...
Read More
biotech policy election year panel at BIO CEO and Investor Conference 2024

What policy biotech should be watching this election year

The biotech industry must constantly navigate the ins and outs of Beltway politics. ...
Read More

EDITORS' CHOICE

surgeon wearing a face mask and PPE

Why the WTO should focus on addressing trade-related aspects of pandemic preparedness

As the 13th Ministerial Conference of the World Trade Organization (WTO) kicks off (Feb. 26-29), the expansion of the COVID-19 IP waiver remains a contentious ...
Read More

LATEST NEWS

BIO Events

Biotech investment is scarce, but still available, experts tell CEOs

Even in this challenging market, biotechnology firms are attracting investment and building capital, but they need more than just a great innovation. They also need ...
BIO Events

What biotech companies should know about M&A in down markets

Mergers and acquisitions (M&A) are important elements of the biotech industry, especially for early-stage fundraising and bringing new drugs and treatments to the market. M&A ...
BIO Events

The future of next-generation obesity drugs

The metabolic field is the hottest biotech therapeutic area of the year (and likely to continue beyond). In the context of a difficult couple of ...
BIO's View

CEOs ask Congress to pass ORPHAN Cures Act

Biotechnology Innovation Organization (BIO) member companies and CEOs sent a letter to congressional leaders urging them to pass the bipartisan ORPHAN Cures Act and support ...
BIO Events

Drug developers and investors need to join AI revolution, panel says

Artificial intelligence and machine learning have boosted drug development and enhanced the value of biotech firms for years, but investors and companies need to ignore ...

BIO to Congress: IRA's price controls harm R&D

Drug price controls in the Inflation Reduction Act (IRA) harm drug R&D, John Crowley, CEO of Amicus Therapeutics and BIO Board Vice Chair, testified on September 21.

AGRICULTURE

Climate Change

gas pump

New Mexico legislature passes clean fuel standard

On February 13, the New Mexico legislature passed a clean fuel standard—which the Biotechnology Innovation Organization (BIO) has long advocated ...
Read More

Federal Policy

State Policy

NYCEDC seeks private-sector life sciences anchor tenant at SPARC Kips Bay

The New York City Economic Development Corporation (NYCEDC) announced on February 26 that it’s seeking a private-sector anchor tenant for ...
Read More

International

Bio's View

CEOs ask Congress to pass ORPHAN Cures Act

Biotechnology Innovation Organization (BIO) member companies and CEOs sent a letter to congressional leaders urging them to pass the bipartisan ...
Read More

GET DAILY BIOTECH NEWS IN YOUR INBOX

Scroll to Top
SUBSCRIBE TO THE FREE GOOD DAY BIO NEWSLETTER